LT3893B - Pharmaceutical composition with nalmefene for treating alcoholism - Google Patents
Pharmaceutical composition with nalmefene for treating alcoholism Download PDFInfo
- Publication number
- LT3893B LT3893B LTIP1486A LTIP1486A LT3893B LT 3893 B LT3893 B LT 3893B LT IP1486 A LTIP1486 A LT IP1486A LT IP1486 A LTIP1486 A LT IP1486A LT 3893 B LT3893 B LT 3893B
- Authority
- LT
- Lithuania
- Prior art keywords
- alcohol
- nalmefene
- patient
- treatment
- rats
- Prior art date
Links
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 title claims abstract description 58
- 229960005297 nalmefene Drugs 0.000 title claims abstract description 58
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 13
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 73
- 230000000694 effects Effects 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 5
- 230000002787 reinforcement Effects 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 2
- 235000013334 alcoholic beverage Nutrition 0.000 abstract 1
- 239000003401 opiate antagonist Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000011514 reflex Effects 0.000 description 10
- 229960003086 naltrexone Drugs 0.000 description 8
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229960004127 naloxone Drugs 0.000 description 5
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003887 narcotic antagonist Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000019525 primary metabolic process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- JYRBQCWXZNDERM-XIRDDKMYSA-N etazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(CC)[C@@H](CC)[C@H]1N(C)CC2 JYRBQCWXZNDERM-XIRDDKMYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009231 family therapy Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- -1 levalorphan Chemical compound 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
- 229950009131 metazocine Drugs 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/532,424 US5086058A (en) | 1990-06-04 | 1990-06-04 | Method for treating alcoholism with nalmefene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP1486A LTIP1486A (en) | 1995-09-25 |
| LT3893B true LT3893B (en) | 1996-04-25 |
Family
ID=24121726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP1486A LT3893B (en) | 1990-06-04 | 1993-11-25 | Pharmaceutical composition with nalmefene for treating alcoholism |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5086058A (de) |
| EP (1) | EP0531415B1 (de) |
| JP (1) | JP3059213B2 (de) |
| AT (1) | ATE145329T1 (de) |
| AU (1) | AU642748B2 (de) |
| CA (1) | CA2084519C (de) |
| DE (1) | DE69123247T2 (de) |
| DK (1) | DK0531415T3 (de) |
| ES (1) | ES2097209T3 (de) |
| FI (1) | FI925513L (de) |
| GR (1) | GR3022289T3 (de) |
| HU (1) | HU210637B (de) |
| IE (1) | IE77333B1 (de) |
| LT (1) | LT3893B (de) |
| LV (1) | LV10190B (de) |
| NZ (1) | NZ238391A (de) |
| RU (1) | RU2090190C1 (de) |
| WO (1) | WO1991018605A1 (de) |
| ZA (1) | ZA914185B (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882335A (en) * | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US6271239B1 (en) * | 1992-04-13 | 2001-08-07 | Regents Of The University Of Minnesota | Delta opioid receptor-selective benzylidene-substituted morphinans |
| US5352680A (en) * | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| US5298622A (en) * | 1993-05-12 | 1994-03-29 | Regents Of The University Of Minnesota | Spiroindane opiate analogs |
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| US5587381A (en) * | 1995-03-27 | 1996-12-24 | Sinclair; John D. | Method for terminating methadone maintenance through extinction of the opiate-taking responses |
| WO1997018781A1 (en) * | 1995-11-20 | 1997-05-29 | University Of Miami | Method of treating nicotine dependence |
| US5878750A (en) * | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| CA2314896C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| JP2001526228A (ja) | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク，エス．エイ． | オピオイド作動薬／拮抗薬の併用 |
| EP1248800A2 (de) * | 1999-11-30 | 2002-10-16 | Corixa Corporation | Kompositionen und methoden zur therapie und diagnose von brustkrebs |
| HU229705B1 (en) | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US20040024004A1 (en) * | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
| RU2227004C2 (ru) * | 2000-06-16 | 2004-04-20 | Писаренко Фаля Юрьевич | Способ лечения наркологической зависимости |
| US6262062B1 (en) * | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6528520B2 (en) * | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| JP4736323B2 (ja) * | 2001-07-13 | 2011-07-27 | アークレイ株式会社 | 分析用具を備えた濃度測定装置用の穿刺要素一体装着体、および体液採取用具 |
| SI1416842T1 (sl) * | 2001-07-18 | 2009-06-30 | Euro Celtique Sa | Farmacevtske kombinacije oksikodona in naloksona |
| ATE431738T1 (de) | 2001-08-06 | 2009-06-15 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
| AU2002324624A1 (en) | 2001-08-06 | 2003-02-24 | Euro-Celtique S.A. | Sequestered antagonist formulations |
| US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| EP1423116A1 (de) * | 2001-08-14 | 2004-06-02 | Biotie Therapies Corp. | Verfahren zur behandlung von alkoholismus oder alkoholmissbrauch |
| RU2215527C2 (ru) * | 2001-09-28 | 2003-11-10 | Областная наркологическая больница | Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза |
| RU2200556C1 (ru) * | 2001-12-05 | 2003-03-20 | Северцев Владимир Алексеевич | Лекарственная форма налтрексона |
| EP1492505B1 (de) | 2002-04-05 | 2015-06-03 | Euro-Celtique S.A. | Pharmazeutische zubereitung enthaltend oxycodon und naloxon |
| US7501433B2 (en) * | 2002-05-17 | 2009-03-10 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US7923454B2 (en) * | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| SI2561860T1 (en) * | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
| US7815934B2 (en) | 2002-09-20 | 2010-10-19 | Alpharma Pharmaceuticals, Llc | Sequestering subunit and related compositions and methods |
| PT1610791E (pt) | 2003-03-31 | 2011-05-23 | Titan Pharmaceuticals Inc | Dispositivo polim?rico implant?vel para liberta??o sustentada de agonista da dopamina |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| EP1613324A2 (de) * | 2003-04-14 | 2006-01-11 | Pain Therapeutics, Inc. | Verfahren zur behandlung von schmerzen mit opioid-antagonisten |
| MY135852A (en) * | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| US8017622B2 (en) | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US20060009478A1 (en) * | 2003-10-15 | 2006-01-12 | Nadav Friedmann | Methods for the treatment of back pain |
| EP1604666A1 (de) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
| EP1702558A1 (de) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
| SI2719378T1 (sl) | 2006-06-19 | 2016-11-30 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
| US7893080B2 (en) | 2006-10-20 | 2011-02-22 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
| US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| EP2224808A4 (de) * | 2007-12-17 | 2013-11-27 | Alpharma Pharmaceuticals Llc | Pharmazeutische zusammensetzung |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| JP5426660B2 (ja) * | 2008-04-24 | 2014-02-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ナルメフェンジ−エステルプロドラッグ |
| CA2722246C (en) * | 2008-04-24 | 2016-06-21 | Janssen Pharmaceutica Nv | Nalmefene prodrugs |
| RU2478388C2 (ru) * | 2008-07-07 | 2013-04-10 | Еуро-Селтик С.А. | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи |
| RU2393864C1 (ru) * | 2008-12-29 | 2010-07-10 | Руслан Дмитриевич Илюк | Средство для профилактики и лечения алкоголизма и опиоидной наркомании |
| MY152279A (en) | 2009-03-10 | 2014-09-15 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US20140005217A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| WO2014170353A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with sleep disorder |
| US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| EP3134090B1 (de) * | 2014-04-22 | 2019-06-05 | Otsuka Pharmaceutical Co., Ltd. | Kombination enthaltend brexpiprazol und nalmefen und deren verwendung zur behandlung von substanzbedingten erkrankungen |
| US10034871B2 (en) | 2014-11-07 | 2018-07-31 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
| CN117137917A (zh) * | 2016-04-22 | 2023-12-01 | 景凯生物科技股份有限公司 | 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857533A (en) * | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
| US4863928A (en) * | 1989-01-04 | 1989-09-05 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for arthritic and inflammatory diseases |
| US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
-
1990
- 1990-06-04 US US07/532,424 patent/US5086058A/en not_active Expired - Lifetime
-
1991
- 1991-05-10 CA CA002084519A patent/CA2084519C/en not_active Expired - Lifetime
- 1991-05-10 AU AU79740/91A patent/AU642748B2/en not_active Expired
- 1991-05-10 WO PCT/US1991/003241 patent/WO1991018605A1/en not_active Ceased
- 1991-05-10 DE DE69123247T patent/DE69123247T2/de not_active Expired - Lifetime
- 1991-05-10 DK DK91910595.7T patent/DK0531415T3/da active
- 1991-05-10 RU RU9192016403A patent/RU2090190C1/ru active
- 1991-05-10 AT AT91910595T patent/ATE145329T1/de not_active IP Right Cessation
- 1991-05-10 EP EP91910595A patent/EP0531415B1/de not_active Expired - Lifetime
- 1991-05-10 JP JP3509984A patent/JP3059213B2/ja not_active Expired - Lifetime
- 1991-05-10 ES ES91910595T patent/ES2097209T3/es not_active Expired - Lifetime
- 1991-05-10 FI FI925513A patent/FI925513L/fi unknown
- 1991-05-10 HU HU9203835A patent/HU210637B/hu unknown
- 1991-06-03 ZA ZA914185A patent/ZA914185B/xx unknown
- 1991-06-04 NZ NZ238391A patent/NZ238391A/en not_active IP Right Cessation
- 1991-06-04 IE IE188891A patent/IE77333B1/en not_active IP Right Cessation
-
1993
- 1993-08-31 LV LVP-93-1052A patent/LV10190B/en unknown
- 1993-11-25 LT LTIP1486A patent/LT3893B/lt not_active IP Right Cessation
-
1997
- 1997-01-16 GR GR960403307T patent/GR3022289T3/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
Non-Patent Citations (2)
| Title |
|---|
| DIXON AT AL.: "Clin.Pharmacol., Vol.27, 1987", pages: 233 - 239 |
| YEOMANS ET AL.: "Psycopharmacology, vol. 100, 1990", pages: 426 - 432 |
Also Published As
| Publication number | Publication date |
|---|---|
| GR3022289T3 (en) | 1997-04-30 |
| EP0531415A1 (de) | 1993-03-17 |
| LV10190A (lv) | 1994-10-20 |
| HUT65523A (en) | 1994-06-28 |
| RU2090190C1 (ru) | 1997-09-20 |
| CA2084519C (en) | 1999-02-09 |
| HU9203835D0 (en) | 1993-03-29 |
| FI925513A7 (fi) | 1992-12-04 |
| ZA914185B (en) | 1992-07-29 |
| EP0531415B1 (de) | 1996-11-20 |
| DE69123247D1 (de) | 1997-01-02 |
| DK0531415T3 (da) | 1996-12-09 |
| CA2084519A1 (en) | 1991-12-05 |
| LTIP1486A (en) | 1995-09-25 |
| AU7974091A (en) | 1991-12-31 |
| US5086058A (en) | 1992-02-04 |
| LV10190B (en) | 1995-06-20 |
| JP3059213B2 (ja) | 2000-07-04 |
| WO1991018605A1 (en) | 1991-12-12 |
| IE77333B1 (en) | 1997-12-03 |
| IE911888A1 (en) | 1991-12-04 |
| HU210637B (en) | 1995-06-28 |
| FI925513A0 (fi) | 1992-12-04 |
| FI925513L (fi) | 1992-12-04 |
| ATE145329T1 (de) | 1996-12-15 |
| JPH06506665A (ja) | 1994-07-28 |
| NZ238391A (en) | 1997-06-24 |
| AU642748B2 (en) | 1993-10-28 |
| ES2097209T3 (es) | 1997-04-01 |
| DE69123247T2 (de) | 1998-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3893B (en) | Pharmaceutical composition with nalmefene for treating alcoholism | |
| Hoehn-Saric et al. | Effects of clonidine on anxiety disorders | |
| Oswald et al. | Some experiments in the chemistry of normal sleep | |
| US5426120A (en) | Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
| Papp et al. | Toxic effects of iproniazid in a patient with angina | |
| US20130039905A1 (en) | Diazoxide For Use In The Treatment Or Prevention Of A Central Nervous System (CNS) Autoimmune Demyelinating Disease | |
| Tennant Jr et al. | Mecamylamine for Withdrawal From Nicotine Dependence | |
| KR100425045B1 (ko) | 약물중독의치료를위한멜라토닌함유약학적조성물 | |
| US20040092509A1 (en) | Use of flumazenil in the production of a drug for the treatment of alcohol dependency | |
| WO2001026638A2 (en) | The use of baclofen in the treatment of alcoholism | |
| KR100712571B1 (ko) | 코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도 | |
| EP1681057A1 (de) | Verwendung von Naloxon zur Behandlung von Essstörungen | |
| BG62876B1 (bg) | Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост | |
| Grupp | Effects of angiotensin II and an angiotensin converting enzyme inhibitor on alcohol intake in P and NP rats | |
| EP3454853B1 (de) | Behandlung von alkoholismus und depression unter verwendung von ibudilast | |
| Ferris et al. | Neuropeptide modulation of cognition and memory in humans. | |
| US6437093B1 (en) | Methods of treatment comprising administration of Substance P | |
| Treiman et al. | Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients | |
| US4861772A (en) | Method and composition to treat panic syndrome | |
| Ban et al. | Psychopharmacology for everyday practice | |
| Nagain‐Domaine et al. | Modulation by alcohol and methadone of 2‐deoxyglucose‐stimulated pancreatic secretion in the rat | |
| Porter | Update of new publications on Neurodegenerative Disorders research | |
| Taylor | Alcohol and the brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC9A | Transfer of patents |
Free format text: CONTRAL CLINICS OY,TAPIOLAN KESKUSTORNI 6KRS, FIN-02100 ESPOO,FI,990910 |
|
| MK9A | Expiry of a patent |
Effective date: 20131125 |